HC Wainwright & Co. Reiterates Buy on Evaxion Biotech, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Evaxion Biotech (NASDAQ:EVAX) and maintained a price target of $14.
November 01, 2024 | 10:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Evaxion Biotech and maintained a $14 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $14 price target by HC Wainwright & Co. suggests positive sentiment and confidence in Evaxion Biotech's future performance. This could lead to a positive short-term impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100